Taking it

Darunavir is licensed in both the European Union and the US for use in both treatment-naive and treatment-experienced people. 

In November 2012, an 800mg tablet received US Food and Drug Administration approval, and was approved in Europe in January 2013. This dosage is approved for treatment-naive and treatment-experienced adults with no darunavir resistance, taken with 100mg of ritonavir. It enables people to take one darunavir pill once a day.

Darunavir 800mg is also approved for use with a 150mg boosting dose of cobicistat. A fixed-dose tablet containing darunavir and cobicistat is also available. See Rezolsta for further details.

Treatment-experienced people should take 600mg twice daily boosted with ritonavir 100mg. Treatment-experienced people without darunavir-associated resistance mutations and viral load below 100,000 copies/ml may take an 800mg dose once daily, boosted with cobicistat.

Darunavir should be taken with food.

Most drug-drug interaction studies used the twice-daily dose of boosted darunavir. Until more data are available, twice-daily dosing should be considered when darunavir is used with efavirenz, nevirapine, and etravirine in treatment-experienced people. However, in combination with raltegravir and maraviroc, once-daily dosing is an option. Neither lopinavir/ritonavir nor saquinavir is recommended for use with darunavir because of a significant decrease in darunavir serum concentration that occurs when these drugs are used together.  

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.